Nephrology Forum

Kidney International (1991) 39, 1034–1050; doi:10.1038/ki.1991.131

Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients

Presentation of the Forum is made possible by grants from Pfizer Incorporated; Merck Sharp & Dohme International; Sandoz, Incorporated; Marion Merrell Dow Incorporated; and Amgen, Incorporated. This Forum was held at the UCSF Medical Center (Moffit Hospital) in San Francisco, California.

Principal discussant Felix J Frey1

1University of California, San Francisco, California

Correspondence: Dr F J Frey, Medizinische Poliklinik, Inselspital Bern, 3010 Bern, Switzerland

Top

References

  1. Newberger J, Kahan BD: Cyclosporine pharmacokinetics in man. Transplant Proc 15:2413–2415, 1983
  2. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ: Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 38:296–300, 1985
  3. Frey FJ, Horber FF, Frey BM: Trough levels and concentration time curve of cyclosporine in patients undergoing renal transplantation. Clin Pharmacol Ther 43:55–62, 1988
  4. Beveridge T, Gratwohl A, Michot F, Niederberger W, Nuesch E et al: Cyclosporin A: Pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts. Curr Ther Res 30:5–18, 1981
  5. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ: The effect of food on cyclosporine absorption. Transplantation 40:174–176, 1985 | PubMed | ChemPort |
  6. Mehta MU, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Delamos B: Effect of bile on cyclosporine absorption in liver transplant patients. Br J Clin Pharmacol 25:579–584, 1988 | PubMed | ChemPort |
  7. Kehrer BH, Whitington PF, Black AD: The effect of Rouxen-y biliary enterostomy on the absorption of cyclosporine: relevance to poor drug bioavailability in children after orthotopic liver transplantation. Transplant Proc 20:523–528, 1988
  8. Atkinson K, Biggs JC, Britton K, Short R, Mrongovius R: Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction. Br J Haematol 56:223–231, 1984 | PubMed | ChemPort |
  9. Atkinson K, Britton K, Palul P, Farrell C, Concannon A: Detrimental effect of intestinal disease on absorption of orally administered cyclosporine. Transplant Proc 15(suppl 1):2446–2449, 1983
  10. Roberts R, Sketris IS, Abraham I, Givner M, MacDonald AS: Cyclosporine absorption in two patients with short-bowel syndrome. Drug Intell Clin Pharmacol 22:570–572, 1988
  11. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Schaffalitzky De Muckadell O, Williams N, MacDonald AS, Tanton R, Molina F, Campanini M, Biahchi P, Ranzi T, Quarto Di Palo F, Malchow-Moller A, Ostergaard Thomsen O, Tage-Jensen U, Vinder V, Rus P: A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 321:845–850, 1989 | PubMed |
  12. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA: The effect of oral metoclopramide on the absorption of cyclosporine. Transplantation 43:211–213, 1987
  13. Kahan BD, Ried M, Newburger J: Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15:446–453, 1983
  14. Maurer G: Metabolism of cyclosporine. Transplant Proc 17:19–26, 1985
  15. Wood AJ, Maurer G, Niederberger W, Beveridge T: Cyclosporine: pharmacokinetics, metabolism and drug interaction. Transplant Proc 15:2409–2412, 1983 | ISI | ChemPort |
  16. Beveridge T: Pharmacokinetics and metabolism of cyclosporine A, in Cyclosporine A, edited by White DJG, New York, Elsevier Biomedical, 1982
  17. Guengerich FP: Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 29:241–264, 1989 | Article | PubMed | ChemPort |
  18. Bertault-Peres P, Bonfils C, Fabre G, Just S, Cano J, Maurel P: Metabolism of cyclosporin A, II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes. Drug Metab Dispos 15(3):391–398, 1987
  19. Kronbach T, Fischer V, Meyer UA: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43:630–635, 1988 | PubMed | ISI | ChemPort |
  20. Maurer G: Metabolism of cyclosporine. Transplant Proc 17(suppl 1):19–26, 1985
  21. Haugen DA, Coon MJ, Nebert DW: Induction of multiple forms of mouse liver cytochrome P-450. Evidence for genetically controlled de novo protein synthesis in response to treatment with beta-naphthoflavone or phenobarbital. J Biol Chem 251:1817–1827, 1976 | PubMed | ChemPort |
  22. Hardwick JP, Gonzalez FJ, Kasper CB: Transcriptional regulation of rat liver epoxide hydratase, NADPH-cytochrome P-450 oxidoreductase, and cytochrome P-450b genes by phenobarbital. J Biol Chem 258:8081–8085, 1983
  23. Fujii-Kuriyama Y, Mizukami Y, Kawajiri K, Sogawa K, Muramatsu M: Primary structure of a cytochrome P-450: Coding nucleotide sequence of phenobarbital-inducible cytochrome P-450 cDNA from rat liver. Proc Nat Acad Sci 79:2793–2797, 1982
  24. Fonne R, Meyer UA: Mechanisms of phenobarbital-type induction of cytochrome P-450 isozymes. Pharmacol Ther 33:19–22, 1987
  25. Ringold GM: Steroid hormone regulation of gene expression. Annu Rev Pharmacol Toxiol 25:529–566, 1985
  26. Goldstein JA: Halogenated Biphenyls, Terphenyls, Naphthalenes, Dibenzodioxins and Related Products, edited by Kim-brough RD, Amsterdam, Elsevier, 1980, pp. 151–190
  27. Remmer H: Induction of drug metabolizing enzyme system in the liver. Eur J Clin Pharmacol 5:116–136, 1972 | Article | ChemPort |
  28. Giger U, Meyer UA: The substituted pyridines metyrapone and nicotinamide are inducers of 5-aminolevulinate synthase and cytochrome P-450 in hepatocyte culture. Biochem Pharmacol 31:1735–1741, 1982
  29. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ: Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051–5060, 1986 | PubMed | ChemPort |
  30. Cunningham C, Burke MD, Wheatley DN, Thomson AW, Simpson JG, Whiting PH: Amelioration of cyclosporin-induced nephrotoxicity in rats by induction of hepatic drug metabolism. Biochem Pharmacol 34 (4) 573–578, 1985 | PubMed |
  31. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG: Evaluation of cyclosporine-phenytoin interaction with observation on cyclosporine metabolites. Br J Clin Pharmacol 18:887, 1984 | PubMed | ChemPort |
  32. Venkataramanan R, Habucky K, Burckart G, Ptachcinski RJ: Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokin 16:134–161, 1989
  33. Rodighiero V: Therapeutic drug monitoring of cyclosporin. Practical applications and limitations. Clin Pharmacokin 16:27–37, 1989
  34. Guengerich FP, Bocker RH: Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihyropyridines. J Biol Chem 263:8168–8175, 1988 | PubMed | ChemPort |
  35. Iaina A, Herzog D, Cohen D: Calcium entry-blockade with verapamil in cyclosporine A plus ischaemia induced acute renal failure in rats. Clin Nephrol 25 (suppl 1):S168–170, 1986
  36. Wagner K, Albrecht S, Neumayer H-H: Prevention of post-transplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 7:287–291, 1987 | PubMed | ChemPort |
  37. Wagner K, Henkel M, Heinemeyer G, Neumayer H-H: Interaction of calcium blockers and cyclosporine. Transplant Proc (no 2, suppl 2) 20:561–568, 1988
  38. Kohlhaw K, Wonigeit K, Frei U, Oldhafer K, Neumann K, Pichlmayr R: Effect of the calcium channel blocker diltiazem on cyclosporine A blood levels and dose requirements. Transplant Proc (vol 20, no 2) 20:572–574, 1988
  39. Bourbigot B, Guiserix J, Airiau J, Bressollette L, Morin JF: Nicardipine increases cyclosporine blood levels. Lancet 1:1447, 1986
  40. Lindholm A, Henricsson S: Verapamil inhibits cyclosporin metabolism. Lancet 1:1262–1263, 1987 | PubMed | ChemPort |
  41. Birx DL, Berger M, Fleischer TA: The interference of T cell activation by calcium channel blocking agents. J Immunol 133:6, 2904–2909, 1984 | PubMed | ChemPort |
  42. McMillin MA, Tesi RJ, Baumgarten WB, Jaffe BM, Wait RB: Potentiation of cyclosporine by verapamil in vitro. Transplantation 40:444–445, 1985
  43. Ferguson RM, Sutherland DER, Simmons RL, Najarian JS: Ketoconazole, cyclosporin metabolism and renal transplantation. Lancet 2:882–883, 1982
  44. Henricsson S, Lindhold A: Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 20:569–571, 1988
  45. Odds FO, Webster CE: Effects of azole antifungals in vitro on host/parasite interactions relevant to candida infections. J Antimicrob Chemother 22(1):173–181, 1988
  46. Senior DS, Shaw JT: In vitro effects of fluconazole (UK-19, 858) and ketoconazole on mouse lymphocyte proliferation and on candida blastospore destruction by human polymorphonuclear leukocytes. Int J Immunopharmacol 10(2):169–173, 1988
  47. Dieperink H, Kemp E, Leyssac PP: Ketoconazole and cyclosporine A: combined effects on rat renal function and on serum and tissue cyclosporine A concentration. Clin Nephrol 25:S137–S143, 1986
  48. White DJG, Blatchford NR, Cauwenberg G: Cyclosporine and ketoconazole. Transplantation 37:214–215, 1984
  49. Anderson JE, Blaschke TF: Ketoconazole inhibits cyclosporine metabolism in vivo in mice. J Pharmacol Exp Ther 236(3):671, 1985
  50. Anderson JE, Morris RE, Blaschke T: Pharmacodynamics of cyclosporine-ketoconazole interaction in mice. Transplantation 43(4):529–533, 1987
  51. Wadhwa NK, Schroeder TJ, Pesce AJ, Myre SA, Clardy CW, First MR: Cyclosporine drug interactions: a review. Ther Drug Monit 9:399–406, 1987
  52. Gupta SK, Bakran A, Johnson WG, Rowland M: Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 25:401–402, 1988 | PubMed | ChemPort |
  53. Sheiner LB, Tozer TN: Clinical pharmacokinetics: the use of plasma concentrations of drugs, in Clinical Pharmacology (2nd ed), edited by Melmon KL, Morelli HF, New York, Macmillan, 1978
  54. Frey FJ, Schaad HJ, Renner EL, Horber FF, Frey BM, Preisig R: Impaired liver function in stable renal allograft recipients. Hepatology 9(4):606–613, 1989
  55. Kahan B, Kramer WG, Wideman C, Flechner SM, Lorber MI: Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41:459–463, 1986 | PubMed | ISI | ChemPort |
  56. Irschik E, Tilg H, Niederwiesser D, Gastl G, Huber CH: Cyclosporine blood levels do correlate with clinical complications. Lancet 2:692–693, 1984
  57. Kennedy MS, Yee GC, McGuire TR, Leonard TM, Crowley JJ: Correlation of serum cyclosporine concentrations with renal dysfunction in marrow transplant recipients. Transplantation 40:249–253, 1985 | PubMed | ChemPort |
  58. Speck RF, Frey FJ, Frey BM: Cyclosporine kinetics in renal transplant patients as assessed by high-performance liquid chromatography and radioimmunoassay using monoclonal and polyclonal antibodies. Transplantation 47(5):802–806, 1989
  59. Grevel J, Welsh MS, Kahan BD: Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough-level monitoring. Ther Drug Monit 11(3):246–248, 1989 | PubMed | ChemPort |
  60. Venkataramanan R, Starzl TE, Ptachcinski RJ, Gray J, Burckart GJ, Van Thiel DH: Cyclosporine kinetics in liver disease. Clin Pharmacol Ther 37:234–239, 1985
  61. Yee GC, Lennon TP, Gmar DJ, Kennedy MS, Deeg HJ: Effect of age on cyclosporine kinetics in marrow transplant recipients. Transplant Proc 19:1704–1705, 1987
  62. Follath F, Wenk M, Vozeh S, Thiel G, Brunner F: Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 34:638–648, 1983
  63. Lindberg A, Odlind B, Tufveson G, Linstrum B, Gabrielsson J: The pharmacokinetics of cyclosporine A in uremic patients. Transplant Proc (suppl) 18:144–152, 1986
  64. Tsang SY, Garovoy MR, Benet LT: Immunosuppressive activity of prednisone and prednisolone and their metabolic interconversion in the mixed lymphocyte reaction. Int J Immunopharmacol 7:731–737, 1985
  65. Frey FJ, Amend WJC Jr, Lozada F, Frey BM, Benet LZ: Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. J Clin Endocrinol Metab 53:1076–1080, 1981 | PubMed | ISI | ChemPort |
  66. Frey FJ, Frey BM, Benet LZ: Liquid-chromatographic measurements of endogenous and exogenous glucocorticoids in plasma. Clin Chem 25:1944–1947, 1979 | PubMed | ChemPort |
  67. Frey BM, Frey FJ: Simultaneous measurement of prednisone, prednisolone and 6beta-hydroxyprednisolone in urine by high-performance liquid chromatography coupled with a radioactivity monitor. J Chromatogr 229:283–292, 1982
  68. Rose IQ, Jusko WJ: Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr 162:273–280, 1979
  69. Behm HL, Wagner JG: Errors in interpretation of data from equilibrium dialysis protein binding experiments. Res Commun Chem Pathol Pharmacol 26:145–160, 1979
  70. Frey BM, Frey FJ, Holford N, Lozada F, Benet LZ: Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. Transplantation 6:578–584, 1982
  71. Frey BM, Hugentobler T, Buhrer M, Frey FJ: Transcortinkonzentrationen im Plasma von Normalpersonen und Patienten mit Nieren-oder Lebererkrankungen. Klin Wochenschr 62:936–938, 1984
  72. Gustavson LE, Benet LZ: The macromolecular binding of prednisone in plasma of healthy volunteers including pregnant women and oral contraceptive users. Pharmacokin Biopharm 13:561–569, 1985
  73. Frey BM, Frey FJ: The effect of altered prednisolone kinetics in patients with the nephrotic syndrome and in women taking oral contraceptive steroids on human mixed lymphocyte cultures. J Clin Endocrinol Metab 60:361–369, 1985 | PubMed | ChemPort |
  74. Slaunwhite WR, Lockie GM, Back N, Sandberg AA: Interactivity in vivo of transcortin bound Cortisol. Science 135:1062–1063, 1962 | PubMed | ChemPort |
  75. Meikle AW, Weed JA, Tyler FH: Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays. J Clin Endocrinol Metab41:717–721, 1975
  76. Rose IQ, Yurchak AM, Jusko WJ: Dose-dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm 9:389–417, 1980
  77. Frey FJ, Amend JW, Lozada F, Frey BM, Holford N, Benet LZ: Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. Eur J Clin Pharmacol 21:235–243, 1981
  78. Legler UF, Frey FJ, Benet LZ: Prednisolone clearance at steady state in humans. J Clin Endocrinol Metab 55:762–767, 1982
  79. Bergrem H: Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney Int 23:876–881, 1983
  80. Boekenoogen SJ, Szefler SJ, Jusko WJ: Prednisolone disposition and protein binding in oral contraceptive users. Clin Endocrinol Metab 56:702–709, 1983
  81. Frey BM, Schaad HJ, Frey FJ: Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. Eur J Clin Pharmacol 26:505–511, 1984 | Article | PubMed | ChemPort |
  82. Frey FJ, Frey BM: Altered prednisolone kinetics in patients with the nephrotic syndrome. Nephron 32:45–48, 1982
  83. Frey FJ, Ruegsegger MK, Frey BM: The dose-dependent systemic availability of prednisone, one reason for the reduced biological effect of alternate-day prednisone. Br J Clin Pharmacol 21:183–189, 1986
  84. Frey BM, Seeberger M, Frey FJ: Pharmacokinetics of 3 different prednisolone prodrugs: Evidence for therapeutic inequivalence in renal transplant patients with rejection. Transplantation 39:270–281, 1985
  85. Frey FJ, Frey BM, Greither A, Benet LZ: Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther 215:287–291, 1980 | PubMed | ChemPort |
  86. Frey FJ: Kinetics and dynamics of prednisolone. Endocr Rev 8:453–473, 1987 | PubMed | ISI | ChemPort |
  87. Frey BM, Frey FJ: Clinical pharmacokinetics of prednisolone and prednisone. Clin Pharmacokinet 19(2):126–146, 1990 | PubMed | ChemPort |
  88. Frey FJ, Horber FF, Frey BM: Altered metabolism and decreased efficacy of prednisolone and prednisone in hyperthyroid patients. Clin Pharmacol Ther 44:510–512, 1988
  89. Zurcher RM, Frey BM, Frey FJ: Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 45:366–372, 1989 | PubMed | ChemPort |
  90. Stuck AE, Frey BM, Frey FJ: Kinetics of prednisolone and endogenous Cortisol suppression in the elderly. Clin Pharmacol Ther 43:354–361, 1988 | PubMed | ChemPort |
  91. Bergrem H: The influence of uremia on pharmacokinetics and protein binding of prednisolone. Acta Med Scand 213:333–337, 1983
  92. Öst L, Bjorkhem I, von Bahr C: Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. Eur J Clin Pharmacol 26:363–369, 1984 | PubMed |
  93. Frey FJ, Frey BM: Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. Am J Kidney Dis 3:339–342, 1984 | PubMed | ChemPort |
  94. Lewis GP, Jusko WJ, Burke CW, Graves L: Prednisone side effects and serum protein levels. Lancet 2:778–781, 1971
  95. Uribe M, Go VLW: Corticosteroid pharmacokinetics in liver disease. Clin Pharmacokinet 4:233–240, 1979
  96. Renner E, Horber FF, Jost G, Frey BM, Frey FJ: Effect of liver function on the metabolism of prednisone and prednisolone in humans. Gastroenterology 90:819–828, 1986
  97. Frey FJ, Frey BM, Schnetzer A, Horber FF: Evidence that cyclosporine A does not affect the metabolism of prednisolone after renal transplantation. Transplantation 43:494–498, 1987
  98. Gambertoglio JG, Frey FJ, Holford NHG, Birnbaum JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O Jr, Amend WC Jr: Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int 21:621–626, 1982 | PubMed |
  99. Rocei ML Jr, Tietze KJ, Lee J, Harris H, Danzeisen J, Burke JF: The effect of cyclosporine on the pharmacokinetics of prednisolone in renal transplant patients. Transplantation 45:656–659, 1988
  100. Frey FJ, Gambertoglio JG, Frey BM, Benet LZ, Amend WJC: Nonlinear plasma protein binding and hemodialysis clearance. Eur J Clin Pharmacol 23:65–74, 1982
  101. Jenkins JS, Sampson PA: Conversion of cortisone to Cortisol and prednisone to prednisolone. Br Med J 2:205–207, 1967
  102. Klotz U, Avant GR, Hoyumpa A: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347–359, 1975 | PubMed | ChemPort |
  103. Krauss JW, Desmond PV, Marshall JP: The effects of aging and liver disease on the disposition of lorazepam in man. Clin Pharmacol Ther 24:411–419, 1978
  104. Roberts R, Wilkinson GR, Branch RA, Schenker S: Effect of age and cirrhosis on the disposition and elimination of chlordiazepoxide. Gastroenterology 75:479–485, 1978
  105. Loose DS, Kan PB, Hirs MA, Marcus RA, Feldman D: Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P-450-dependent enzymes. J Clin Invest 71:1495–1499, 1983 | PubMed | ISI | ChemPort |
  106. Brown MW, Maldonado AL, Meredith CG, Speeg KV Jr: Effect of ketoconazole on hepatic oxidative drug metabolism. Clin Pharmacol Ther 37:290–297, 1985
  107. Morrison PJ, Rogers HJ, Bradbrook ID, Parsons C: Concurrent administration of cimetidine and enteric-coated prednisolone: effect on plasma levels of prednisolone. Br J Clin Pharmacol 10:87–89, 1980
  108. Sirgo MA, Rocei ML, Ferguson RK, Eskelman FN, Veanes PH: Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. Clin Pharmacol Ther 37:534–538, 1985
  109. Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector LS, Turchak AM, Andrews F, Jusko WJ: Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 69:455–460, 1982
  110. Langhoff E, Madsen S, Hvidberg E: Inhibition of prednisolone metabolism by cyclosporine in kidney-transplanted patients. Transplantation 39:107–109, 1985
  111. Öst L, Klintmalm G, Ringden O: Mutual interaction between prednisone and cyclosporine in renal transplant patients. Transplant Proc 17:1252–1254, 1985
  112. Ortiz de Montellano RR, Kunze KL, Yost GS, Mico BA: Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proc Natl Acad Sci USA 76:746–749, 1979
  113. Gustavson LE, Legler UF, Benet LZ: Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 62:234–237, 1986 | PubMed | ChemPort |
  114. Meffin PJ, Wing LMH, Sallustio BC, Brooks PM: Alterations in prednisolone disposition as a result of oral contraceptive use and dose. Br J Clin Pharmacol 17:655–664, 1984 | PubMed | ChemPort |
  115. Bartoszek M, Brenner AM, Szefler SJ: Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 42:424–432, 1987
  116. Bergrem H, Refvem OK: Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Med Scand 213:339–343, 1983
  117. Brooks PM, Buchanan WW, Grove M, Downie WW: Effects of enzyme induction on metabolism of prednisolone. Ann Rheum Dis 35:339–343, 1976
  118. Petereit LB, Meikle AW: Effectiveness of prednisolone during phenytoin therapy. Clin Pharmacol Ther 22:912–916, 1977
  119. Frey FJ, Frey BM: Urinary 6beta-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism. J Lab Clin Med 101:593–604, 1983 | PubMed | ChemPort |
  120. Legler UF: Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves ophthalmopathy. Horm Metab Res 19:168–170, 1987
  121. Legler UF: Impairment of prednisolone disposition in patients with Graves disease taking methimazole. J Clin Endocrinol Metab 66:221–223, 1988
  122. McGuire JS Jr, Tomkins GM: The effects of thyroxin administration on the enzymic reduction of A Delta4-3-ketosteroids. J Biol Chem 234:791–794, 1959
  123. Tomkins GM: The enzymatic reduction of Delta4-3 ketosteroids. J Biol Chem 225:13–24, 1957 | PubMed | ISI | ChemPort |
  124. Rumbaugh RC, Kramer RE, Colby HD: Dose-dependent actions of thyroxine on hepatic drug metabolism in male and female rats. Biochem Pharmacol 27:2027–2031, 1978
  125. Frey BM, Frey FJ: Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. Eur J Clin Invest 14:1–6, 1984
  126. Kort WJ, Weijma IM, Westbroek DL: Reductive effect of phenobarbital on graft survival in prednisolone-treated rats. Eur Surg Res 11:317–324, 1979
  127. Wassner SJ, Pennisi AJ, Malekzadeh MH, Fine RN: The adverse effect of anticonvulsant therapy on renal allograft survival. J Pediatr 88:134–137, 1976
  128. Wassner SJ, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN: Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol 8:293–297, 1977
  129. Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM, Lemann J Jr: Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA 236:1958–1960, 1976 | PubMed |
  130. McAllister WAC, Thompson PF, Al-Habet SM, Rogers HJ: Rifampicin reduced effectiveness and bioavailability of prednisolone. Br Med J 286:923–925, 1983 | ChemPort |
  131. Powell-Jackson PR, Gray BJ, Heaton RW, Costello JF, Williams R, English J: Adverse effect of rifampicin administration on steroid-dependent asthma. Am Rev Resp Dis 128:307–310, 1983
  132. Hendrickse W, Mickiernan J, Pickup M, Lowe J: Rifampicin-induced non-responsiveness to corticosteroid treatment in nephrotic syndrome. Br J Med 1:306, 1979
  133. Spangler AS, Antoniades HN, Sotman SL, Inderbitzin TM: Enhancement of the anti-inflammatory action of hydrocortisone by estrogens. J Clin Endocrinol Metab 29:650–655, 1969 | PubMed | ChemPort |
  134. Nelson DH, Tanney H, Mestman G, Gieschen VW, Wilson LD: Potentiation of the biologic effect of administered Cortisol by estrogen treatment. J Clin Endocrinol Metab 23:261–265, 1963 | PubMed | ChemPort |
  135. Frey BM, Frey FJ, BeneT LZ, Cochrum KC: Modification of the mixed lymphocyte reaction for pharmacokinetic assessment of immunosuppressive activity in human plasma. Int J Immunopharmacol 2:129–134, 1980
  136. Frey BM, Walker C, Frey FJ, de Weck AL: Pharmacokinetics and pharmacodynamics of 3 different prednisolone prodrugs: Effect on circulating lymphocyte subsets and function. J Immunol 133:2479–2487, 1983
  137. Frey FJ, Lozada F, Guentert T, Frey BM: A single dose of azathioprine does not affect the pharmacokinetics of prednisolone. Eur J Clin Pharmacol 19:209–212, 1981
  138. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Garovoy MR, Benet LZ: Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. Clin Pharmacol, in press
  139. Smith PC, McDonagh F, Benet LZ: Irreversible binding of zomepirac to plasma protein in vitro and in vivo. Clin Invest 77:934–939, 1986
  140. Ehninger G, Jaschonek K, Schuler U, Kruger HU: Interaction of fluconazole with cyclosporine. (letter) Lancet 1:1262, 1988
  141. Sugar AM, Saunders C, Idelson BA, Bernard DB: Interaction of fluconazole and cyclosporine. (letter) Ann Intern Med 110:844, 1989 | PubMed |
  142. First R, Weiskittel P, Alexander JW, Schroeder TJ, Myre SA, Pesce AJ: Concomitant administration of cyclosporine and ketoconazole in renal transplant recipients. Lancet 2:1198–1201, 1989
  143. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ: Effect of ketoconazole on methylprednisolone pharmacokinetics and Cortisol secretion. Clin Pharmacol Ther 39:654–659, 1986 | PubMed | ChemPort |
  144. Showstack J, Katz P, Amend W, Bernstein L, Lipton H, O'Leary M, Bindman A, Salvatierra O: The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Engl J Med 321:1086–1092, 1989
  145. Elion GB, Callahan S, Nathan H, Bieber S, Rundles BW, Hitching GH: Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem Pharmacol 12:85–93, 1963 | Article | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT